<DOC>
	<DOCNO>NCT00790205</DOCNO>
	<brief_summary>This clinical trial design ass cardiovascular outcome long-term treatment sitagliptin use part usual care compare usual care without sitagliptin participant type 2 diabetes mellitus ( T2DM ) history cardiovascular ( CV ) disease hemoglobin A1c ( HbA1c ) 6.5 % 8.0 % . Primary hypothesis A sitagliptin , use part usual care , non-inferior usual care without sitagliptin regard risk develop confirmed event primary CV composite endpoint Major Adverse Cardiovascular Event ( MACE ) plus . If hypothesis A satisfy : hypothesis B sitagliptin , use part usual care , superior usual care without sitagliptin regard risk develop confirmed event primary CV composite endpoint .</brief_summary>
	<brief_title>Sitagliptin Cardiovascular Outcomes Study ( MK-0431-082 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Has T2DM Has HbA1c 6.5 % ( 48 mmol/mol ) 8.0 % ( 64 mmol/mol ) stable dose ( ) antihyperglycemic agent ( ) , include insulin Has preexisting cardiovascular disease Has history type 1 diabetes mellitus ketoacidosis . Is able take sitagliptin</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>